PrimeRFP SCOUT · Federal Contract Recompete Brief

36C25725N0084Ga68 PSMA injection — Telix Pharmaceuticals (Us) Inc

Telix Pharmaceuticals (Us) Inc holds $6.9M across 17 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 1 related award under parent 36F79722D0197. Competition previously drew 2 offers. PoP ended Oct 24, 2025 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

257-Network Contract Office 17 (36C257)

Awarding office

Telix Pharmaceuticals (Us) Inc

Recipient

Oct 24, 2025

PoP end

$165K

Obligated

$165K

Potential

325412

NAICS

6505

PSC

2 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Telix Pharmaceuticals (Us) Inc — $90

Contract facts

Federal

Contract number36C25725N0084

Also listed as36C257-25-N-0084

Also listed as36F79722D0197-36C25725N0084

Agency257-Network Contract Office 17 (36C257)

Awarding office257-Network Contract Office 17 (36C257)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentTelix Pharmaceuticals (Us) Inc

CAGE8CP27

UEINMRHMBK4YTH7

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79722D0197

Place of performanceFISHERS IN

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startOct 25, 2024

PoP end (current)Oct 24, 2025

Obligated$165K

Current value$165K

Potential value$165K

GA68 PSMA INJECTION is a federal award for 257-Network Contract Office 17 (36C257) held by Telix Pharmaceuticals (Us) Inc. Estimated value $165K ($165K obligated). Current period of performance ends Oct 24, 2025. Last award drew 2 bidders. Place of performance: FISHERS IN.

Recompete timing

Public

● Past PoP end (301 days ago)

Current PoP ended Oct 24, 2025 (301 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Telix Pharmaceuticals (Us) Inc — $6.9M obligated across 17 awards (firm-wide, all agencies).

Sole agency: Department of Veterans Affairs (VA)

Department of Veterans Affairs (VA)$6.9M · 100% of firm total

Open full company profile →

Related awards

Same parent · incumbent

36C24826N0054

ILLUCCIX

$1.8M

Sep 30, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C25725N0084?

36C25725N0084 (Ga68 PSMA injection) is a 257-Network Contract Office 17 (36C257) award with a potential value of $165K, currently held by Telix Pharmaceuticals (Us) Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C257-25-N-0084?

36C257-25-N-0084 is the dashed form of PIID 36C25725N0084 (Ga68 PSMA injection), held by Telix Pharmaceuticals (Us) Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C25725N0084?

257-Network Contract Office 17 (36C257) awarded 36C25725N0084 to Telix Pharmaceuticals (Us) Inc (potential $165K).

Who is the incumbent on 36C25725N0084?

Telix Pharmaceuticals (Us) Inc is the incumbent with $6.9M across 17 related awards in SCOUT’s public footprint. The current period of performance ends Oct 24, 2025.

When does Telix Pharmaceuticals (Us) Inc’s 36C25725N0084 come up for recompete?

SCOUT tracks a period-of-performance end of Oct 24, 2025. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jun 26, 2026 · refreshed monthlyLatest procurement action Oct 16, 2024